CA-AGENDIA-INC
Agendia, Inc. , a world leader in precision oncology for breast cancer, today announced that additional data from its groundbreaking MINDACT study will be highlighted in an oral presentation by Laura van ’t Veer, Ph.D., Co-founder and Chief Research Officer, at the 2020 San Antonio Breast Cancer Symposium (SABCS 2020). These data highlight the ability of MammaPrint® , Agendia’s 70-gene breast cancer recurrence assay, to further stratify patients with clinically low risk breast cancer which could impact physician-patient discussions and treatment planning.
MINDACT (Microarray In Node-Negative and 1-3 node-positive Disease may Avoid ChemoTherapy), the Phase 3, prospective, randomized clinical trial supported by the European Organization for Research and Treatment of Cancer (EORTC), was designed to determine whether MammaPrint could be used to safely de-escalate patients with early stage breast cancer from chemotherapy without compromising their outcomes. Updated outcome and treatment data from the trial shared at SABCS 2020 build upon nearly 9-year follow-up results debuted at ASCO 2020 and confirm MINDACT as a positive de-escalation study.
Dr. van ’t Veer’s presentation showed that the combination of clinical low risk and MammaPrint Low Risk results indicate excellent 8-year prognosis – these patients showed a distant metastasis-free survival rate of 94.7% with no chemotherapy. Of note, amongst the clinically low risk study population, distant metastasis free survival at 8 years was 3.6% better in MammaPrint Low Risk patients as compared to those with a High Risk result.
“Collectively, these data produce a significant library of evidence that will allow for the precise treatment of breast cancer, including insights into a patient population considered low risk,” said Dr. van ’t Veer. “Within this population, further stratification by genomic signature into MammaPrint Low or High Risk should be weighed for further treatment planning.”
These data are part of a large suite of 13 posters, spotlight sessions and an oral presentation on MammaPrint and BluePrint that were accepted to SABCS 2020, and underscore Agendia’s mission to help guide the diagnosis and personalized treatment of breast cancer for all patients throughout their treatment journey.
About Agendia
Agendia is a precision oncology company headquartered in Irvine, California, committed to bringing early stage breast cancer patients and their physicians the information they need to make the best decisions for the full treatment journey. The company currently offers two commercially-available genomic profiling tests, supported by the highest levels of clinical and real world evidence, that provide comprehensive genomic information that can be used to identify the most effective breast cancer treatment possible for each patient.
MammaPrint® , the 70-gene breast cancer recurrence assay, is the only FDA-cleared risk of recurrence test backed by peer-reviewed, prospective outcome data and inclusion in both national and international treatment guidelines. BluePrint® , the 80-gene molecular subtyping assay, is the only commercially-available test that evaluates the underlying biology of a tumor to determine what is driving its growth. Together, MammaPrint® and BluePrint® provide a comprehensive genomic profile to help physicians make more informed decisions in the pre- and post-operative treatment settings.
Agendia develops evidence-based novel genomic tests and forges partnerships with groundbreaking companies to develop next-generation digital treatment tools. The ongoing research builds an arsenal of data that improve patient outcomes and support the evolving clinical needs of breast cancer patients and their physicians every step of the way, from initial diagnosis to cancer-free.
Agendia’s assays can be ordered on core biopsies or surgical specimens to inform pre- and post-operative treatment decisions. For more information on Agendia’s assays and ongoing trials, please visit www.agendia.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20201211005005/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SE Labs Award Reinforces NetApp Status as the Most Secure Storage on the Planet2.7.2025 14:00:00 CEST | Press release
NetApp wins 2025 SE Labs Award for Enterprise Data Protection NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced that it was recognized as a standout performer in cybersecurity in the SE LABS ® Awards 2025. NetApp won the 2025 SE Labs Award for Enterprise Data Protection, validating NetApp’s status as the most secure storage on the planet. This recognition as a winner of a 2025 SE Labs Award is a result of NetApp’s exceptional innovation in cyber resiliency to deliver NetApp ONTAP® Autonomous Ransomware Protection with Artificial Intelligence (ARP/AI), which was tested and validated by SE Labs. NetApp ARP/AI demonstrated 99 percent detection of tested, advanced full-file encryption ransomware attacks with zero false positives, indicating a strong ability to operate in a business context without contributing to alert fatigue. “Great security doesn’t just happen—it’s built, tested and proven,” says Simon Edwards, Founder and CEO of SE Labs. “Behind every
CroíValve Announces Funding from Horizon Europe EIC Accelerator2.7.2025 14:00:00 CEST | Press release
CroíValve, a pioneering medical device company innovating a better way to help more patients suffering from Tricuspid Regurgitation (TR), was awarded funding from Horizon Europe’s European Innovation Council (EIC) Accelerator Programme. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250702306192/en/ DUO™ Transcatheter Tricuspid System Part of the EU’s Horizon Europe 2021-2027 Research and Innovation Programme, the EIC Accelerator Programme provides transformational funding to high-potential, high-risk start-ups, scale-ups and subject matter experts. This award includes grant funding of €2.5 million, combined with an equity investment of €10 million in CroiValve’s next financing. The latest competition included 959 applications, with only 40 awards across 16 countries. Almost one third of the selected companies are led by a woman and CroiValve are incredibly proud to be one of this group. “Securing European Innovation Council
EUMETSAT: Europe’s First Geostationary Sounder Satellite Is Launched2.7.2025 13:20:00 CEST | Press release
Europe has taken a major step forward in strengthening its resilience to extreme weather events with the successful launch of the Meteosat Third Generation Sounder 1 (MTG-S1) satellite. MTG-S1 will deliver new streams of atmospheric data, enabling earlier, more accurate warnings that protect lives, property and infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250702002782/en/ MTG-S1 is part of the Meteosat Third Generation programme, Europe’s new fleet of geostationary meteorological satellites. Image: EUMETSAT Extreme weather events like storms, flooding, and heatwaves have caused hundreds of billions of euros in damage and claimed tens of thousands of lives across Europe in the past decades. Launched on 1 July 2025, MTG-S1 will provide Europe’s national meteorological services with high-frequency data on temperature, humidity and trace gases throughout the atmosphere – enabling forecasters to detect the earli
HCLTech and Equinor Expand Digital Collaboration2.7.2025 13:08:00 CEST | Press release
HCLTech, a global technology leader, and Equinor, Europe's largest energy supplier and a pioneer in renewables and low-carbon solutions, have expanded their IT collaboration to support the next phase of Equinor’s digital transformation. This expanded relationship will cover Equinor’s IT landscape across several key strategic areas. HCLTech will support Equinor as it accelerates its digital transformation by: Accelerating its cloud migration and standardizing services across operations Enhancing its cyber resilience and network performance Improving workplace experience through automation Enabling advanced user experiences with technologies like augmented reality (AR) "We’re pleased to continue our long-standing collaboration with Equinor," said Sandeep Kumar Saxena, Executive Vice President, HCLTech. "This collaboration reflects our shared commitment to innovation and sustainability.” Over the past decade, HCLTech has been a trusted advisor to Equinor, supporting the company’s global e
Wizz Air Tops Major Airline Emissions Rankings2.7.2025 11:00:00 CEST | Press release
Cirium, the aviation analytics company, creates a new transparent standard and ranking for airline CO2 emissions, identifying the best performing airlines in specific categories Wizz Air is the world's most emissions-efficient airline in new rankings released today by Cirium, the aviation analytics firm. The Cirium Flight Emissions Review ranks the top 20 airlines globally, through a consistent benchmark for flight emissions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250702342529/en/ The top 20 Major airlines globally, ranked by lowest CO2/ASK Wizz Air, the Hungary-based ultra-low-cost airline emits an industry low of 53.9 grams of CO₂ per Available Seat Kilometer (ASK)*, followed by Frontier Airlines (54.4 grams) and Pegasus (57.1 grams) according to the report. The rankings provide the aviation industry with verified comparable data on an equal playing field as the sector advances toward Net Zero by 2050 commitments.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom